# Microvisk Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/microvisk-technologies

- Industry: Medical Devices & Equipment
- Headquarters: UK
- Website: www.microvisk.com
- Total disclosed funding: $16M
- Latest round: Series C (Jan 26, 2011)
- Investors on record: 5

## About

Microvisk Technologies Ltd. specializes in advanced at-home blood testing solutions, focusing on enhancing patient convenience and safety through innovative technology.Microvisk Technologies Ltd. develops cutting-edge blood testing solutions, specifically for INR monitoring in patients on anticoagulation therapy. Founded in 2004 in the UK, the company has undergone strategic pivots to enhance its product offerings. The firm operates globally, although specific office locations were not provided. Financing rounds include a Series C in January 2011, where they raised GBP 6 million from investors such as Development Bank of Wales and Oxford Technology Management, marking a total of GBP 6 million raised to date. The company has completed four deals overall.Microvisk primarily offers its innovative CoagMax® Smart Strip technology, which facilitates at-home INR (International Normalized Ratio) blood testing for patients requiring anticoagulation therapy. This technology enables users to conduct testing without needing to visit specialized clinics, thereby enhancing convenience and safety. The Smart Strip employs highly sensitive sensors to detect minute changes in blood viscosity, using only 5µL of blood, making the testing process less painful and more efficient. The product features an embedded memory chip for data storage, which enhances accuracy by tracking calibration data and lot information, and is equipped with on-board quality control sensors that monitor humidity and temperature conditions. Microvisk's client base includes healthcare providers, clinics, and patients primarily in European and North American markets who require regular anticoagulation monitoring.Microvisk’s revenue model centers on direct sales of its CoagMax® Smart Strip and associated testing devices, targeting both healthcare professionals and end consumers. This model encompasses partnerships with healthcare institutions and pharmacies to distribute their products, ensuring accessibility for patients managing their anticoagulation therapy. The company’s testing strips, sold in boxes of 24 or 48, represent a significant product line, ensuring ongoing revenue through repeat purchases as patients require continuous monitoring. The firm’s approach to integrating technology with patient care fosters a direct-to-consumer sales strategy while also maintaining business-to-business relationships with healthcare providers, effectively streamlining patient access to essential testing resources.Following the Series C financing in January 2011, Microvisk Technologies Ltd. is focusing on the development of new products to enhance their testing capabilities. The company is exploring expansion into new geographic markets, particularly targeting broader outreach within the European and North American healthcare sectors by 2013. The GBP 6 million raised will support research and development initiatives aimed at launching additional product offerings and increasing market presence.

## Funding rounds

- Series C, Jan 26, 2011, $9.4M — Oxford Technology Management, Future Planet Capital Regional, New Hill Management, Development Bank of Wales, Porton Capital
- Series B, Sep 9, 2010, $3.9M — Oxford Technology Management, Future Planet Capital Regional, New Hill Management, Development Bank of Wales, Porton Capital
- Series A, Jan 28, 2010, $3.2M — Oxford Technology Management, Future Planet Capital Regional, New Hill Management, Development Bank of Wales
- Seed, Jun 1, 2004 — Future Planet Capital Regional

## Investors

- Future Planet Capital Regional (https://capitalatlas.ai/funds/future-planet-capital-regional) — Seed, Series A, Series B, Series C
- Oxford Technology Management (https://capitalatlas.ai/funds/oxford-technology-management) — Series A, Series B, Series C
- New Hill Management (https://capitalatlas.ai/funds/new-hill-management) — Series A, Series B, Series C
- Development Bank of Wales (https://capitalatlas.ai/funds/development-bank-of-wales) — Series A, Series B, Series C
- Porton Capital — Series B, Series C